|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, we identified ETS1 (v-ets avian erythroblastosis virus E26 oncogene homolog 1) as the target of miR-145.
|
31219744 |
2019 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The intracellular multidrug resistance 1 (MDR1) mRNA and upstream erythroblastosis virus E26 oncogene homolog 1 (ETS1) mRNA can be silenced by MBs, which can effectively inhibit the expression of P-gp and further prevent the efflux of Dox and reverse MDR.
|
29663807 |
2018 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daxx acts as a suppressor of promoter activity by binding to the avian erythroblastosis virus E26 oncogene homolog 1 (Ets-1), which is the core transcription factor required for the expression of EGFL7.
|
29416688 |
2018 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through the Gene Expression Omnibus (GEO) database, the Cancer Genome Atlas (TCGA) database and immunohistochemical (IHC) staining, we observed that compared with adjacent normal renal tissues, in ccRCC tissues the mRNA and protein levels of MMP9 were enhanced, and the mRNA levels of GTP-binding protein smg p21B(RAP1B), B rapidly accelerated fibrosarcoma (RAF), methyl ethyl ketone2 (MEK2), extracellular regulated protein kinases1 (ERK1), ERK2, v-ets avian erythroblastosis virus E26 oncogene homolog1 (ETS1) and ETS2 also increased.
|
30013825 |
2018 |
|
Erythroblastosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of erythroblastosis virus E26 oncogene homolog 1 (ETS1) gene is correlated with both tumor progression and poor response to chemotherapy in cancer treatment, and the exploitation of RNA interference (RNAi) technology to downregulate ETS1 seems to be a promising approach to reverse multidrug-resistant cancer cells to chemotherapy.
|
28302581 |
2017 |
|
Erythroblastosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expression levels of signaling molecules including erythroblastosis 26-1 (Ets-1), extracellular signal-related kinases (ERK) and phosphorylated-ERK were measured by western blotting.
|
28693200 |
2017 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we examined whether v-ets erythroblastosis virus E26 oncogene homologue 1 (Ets-1), an important regulator of different genes, is involved in destabilizing S plaques in patients with carotid stenosis.
|
26254334 |
2015 |
|
Erythroblastosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identify a functional -73G>A mutation in the promoter of TBX22, which is located at the core-binding site of transcription factor ETS-1 (v-ets avian erythroblastosis virus E26 oncogene homolog 1).
|
25373698 |
2015 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the roles of other genes, such as CSF3 (colony stimulating factor 3 receptor), CD40, TNFSF14 (tumor necrosis factor receptor superfamily, member 14), IFNB1 (interferon-β1), TIRAP (toll-interleukin 1 receptor domain containing adaptor protein), IL2RA (interleukin 2 receptor α), ETS1 (v-ets avian erythroblastosis virus E26 oncogene homolog 1), GADD45B (growth arrest and DNA-damage-inducible 45 β), BIRC3 (baculoviral IAP repeat containing 3), VAV1 (vav 1 guanine nucleotide exchange factor), COL5A1 (collagen, type V, α1), and C3 (complement component 3), have not been investigated thoroughly in the process of periodontitis.
|
24476546 |
2014 |
|
Erythroblastosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the transcription factor v-ets erythroblastosis virus E26 oncogene homolog 1 (ETS-1), which inhibited miR-320a expression, was activated in chemoresistant cancer cells; such activation was associated with hypomethylation of the ETS-1 promoter.
|
25159093 |
2014 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promoter analysis suggests that the CD44 promoter contains binding sites of the ETS-1 (v-ets erythroblastosis virus E26 oncogene homolog 1) transcriptional factor.
|
24064218 |
2013 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we addressed the hypothesis that transcriptional suppression of erythroblastosis virus E26 oncogene homolog 1 (ETS-1) is an efficient therapeutic approach to pancreatic adenocarcinoma by investigating the effect of ETS-1 suppression in human pancreatic cancer cells.
|
18772901 |
2009 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that exogenously added histamine stimulates Ets-1 (v-ets erythroblastosis virus E26 oncogene homolog 1) synthesis in human melanoma cells.
|
15848191 |
2005 |